RxDoctor Payments Data

Allan Hunter, MD

Retina Specialist · Eugene, ORNPI 1184748030

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $863, 2.2 times the $392 reported in 2019.

$2,909in general payments, 2019–2025

Across 117 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$679
  • Genentech USA, Inc.$452
  • Novartis$371
  • Apellis Pharmaceuticals, Inc.$276
  • Regeneron Healthcare Solutions, Inc.$267
  • Alcon$147
  • plus $716 from 11 others
$595,291in research payments, 2019–2025

Across 61 payments — averaging $9758.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$181K
  • Genentech, Inc.$156K
  • AstraZeneca$142K
  • Janssen Research & Development, LLC$85K
  • Regeneron$12K
  • Eyepoint US, Inc.$11K
  • plus $8K from 1 others

What the payments were for

  • Food & beverage$2,909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,909 in reported general payments places this provider in the 65th percentile of 36 retina specialist providers in Oregon.

See all retina specialist providers in Oregon

Medicare billing

Part B allowed, 2024
$6,184,866
Medicare patients
992
Services billed
117,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate152$6,797
Bromfenac Sodium50$6,171
Ketorolac Tromethamine198$4,736
ProlensaBromfenac Sodium13$4,110
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat159$2,742
Diclofenac Sodium153$1,687
MoxifloxacinMoxifloxacin Hcl52$1,501
Latanoprost86$950
Timolol Maleate72$651
Atropine Sulfate13$540
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$252
Brimonidine Tartrate25$191
Dorzolamide Hcl17$188
Ofloxacin15$151

Paid to pharmacies, not to this prescriber.

Other retina specialist in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →